

Table S1 Quality evaluation of enrolled studies in meta-analysis.

Reference	Year	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
Hiraide <i>et al</i>	2020	1	0	1	1	1	1	1	0	0	1	0
Dou <i>et al</i>	2020	1	1	1	1	1	1	1	0	0	1	1
Chiari <i>et al</i>	2020	1	1	0	1	1	1	0	0	0	1	0
Samkari <i>et al</i>	2020	1	1	1	1	1	1	1	0	0	1	0
Alexander <i>et al</i>	2020	1	1	1	1	1	1	0	0	0	1	0
Ng <i>et al</i>	2019	1	1	1	1	1	1	1	0	0	1	0
Gervaso <i>et al</i>	2019	1	1	1	1	1	0	0	0	0	1	0
Zer <i>et al</i>	2019	1	1	1	1	1	1	0	0	0	1	0
Yang <i>et al</i>	2019	1	1	1	1	1	0	0	0	0	1	0
Chen <i>et al</i>	2019	1	1	1	1	1	1	1	0	0	1	0
Itchins <i>et al</i>	2018	1	1	1	1	1	0	0	0	0	1	0
Zugazagoitia <i>et al</i>	2018	1	1	1	1	1	1	1	0	0	1	0
Dou <i>et al</i>	2018	1	1	1	1	1	1	1	0	0	1	0
Alexander <i>et al</i>	2018	1	1	1	1	1	0	0	0	0	1	0
Davidsson <i>et al</i>	2017	1	1	1	1	1	1	0	0	0	1	0
Azevedo <i>et al</i>	2017	1	1	1	1	1	1	0	0	0	1	0
Zer <i>et al</i>	2016	1	0	1	1	1	1	1	0	0	1	0
Castellón <i>et al</i>	2015	1	1	1	1	1	0	0	0	0	1	0
Corrales-Rodriguez <i>et al</i>	2014	1	1	1	1	1	1	1	0	0	1	0
Verso <i>et al</i> .	2014	1	1	1	1	1	0	0	0	0	1	0

1) Defines the source of information (e.g., survey, record review).

2) Lists inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications.

3) Indicates time period used for identifying patients.

4) Indicates whether or not subjects were consecutive if not population-based.

5) Indicates if evaluators of subjective components of study were masked to other aspects of the status of the participants.

6) Describes any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements).

7) Explains any patient exclusions from analysis.

8) Describes how confounding was assessed and/or controlled.

9) If applicable, explains how missing data were handled in the analysis.

10) Summarizes patient response rates and completeness of data collection.

11) Clarifies what follow-up, if any, was expected and the percentage of patients with incomplete data or follow-up.




Figure S1 Sensitivity and publication bias of enrolled studies. (A) Sensitivity analysis of all the studies enrolled. (B) Funnel plot of publication bias of total studies. (C) Funnel plot of publication bias of total studies in the subgroup meta-analysis of ROS1-fusion non-small cell lung cancer.




Figure S2 Representative images of ultrasound and computed tomography for the diagnosis of pulmonary embolism or deep vein thrombosis. (A) pulmonary embolism; (B) pulmonary embolism; (C) Jugular vein thrombosis; (D) Femoral vein thrombosis.




Figure S3 Subgroup analyses of PFS in ALK-fusion patients treated with crizotinib or alectinib. (A) Response to crizotinib; (B) PFS of patients treated with crizotinib; (C) response to alectinib; (D) PFS of patients treated with alectinib. ALK, anaplastic lymphoma kinase; PFS, progression-free survival.